Jason R. Kelly - Jan 17, 2023 Form 4 Insider Report for Ginkgo Bioworks Holdings, Inc. (DNA)

Signature
/s/ Karen Tepichin, Attorney-in-Fact
Stock symbol
DNA
Transactions as of
Jan 17, 2023
Transactions value $
-$776,716
Form type
4
Date filed
1/19/2023, 05:19 PM
Previous filing
Jan 17, 2023
Next filing
Jan 20, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNA Class A Common Stock Sale -$282K -152K -0.93% $1.86 16.2M Jan 17, 2023 Direct F1
transaction DNA Class A Common Stock Sale -$192K -100K -0.62% $1.92 16.1M Jan 18, 2023 Direct F2, F3
transaction DNA Class A Common Stock Sale -$302K -155K -0.96% $1.95 15.9M Jan 18, 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction.
F2 The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.81 to $2.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Remarks:

CEO & Founder